Tempus AI shows long-term promise with strong oncology testing and expanding market despite mixed Q1 results.

Tempus AI reported mixed Q1 results with strong oncology testing but weakness in hereditary testing, slower revenue growth, yet improved gross margins and narrowing losses. The company achieved a record $1.1 billion total contract value and 126% net revenue retention, highlighting strong client loyalty and a growing market beyond oncology. Despite some near-term risks and slower growth, the stock remains attractive due to valuation contraction enhancing its risk/reward profile. The analyst maintains a buy rating based on Tempus AI's durable value proposition and expanding addressable market.